Japan’s THC Guidelines: A Step Forward or Just More Confusion?
Japan’s Ministry of Health, Labor and Welfare (MHLW) is gearing up for new rules regarding THC limits in CBD products, set to take effect in December 2024. However, industry experts are raising concerns that these updated guidelines may not fully address the complexities of the cannabis market.
Dr. Yuji Masataka, Japan’s first medical cannabis specialist, has voiced his apprehensions. He argues that the guidelines lack clarity in defining THC thresholds across various product categories, including oils, powders, and aqueous solutions. Masataka believes that additional categories for raw materials and a revision of existing definitions are necessary for a comprehensive approach.
Among the key updates, the guidelines specify that oils must contain more than 90% glycerin and fatty acid compounds, which could limit CBD oil concentrations. Additionally, a threshold of 10 parts per million (ppm) is suggested for CBD oil, hemp seed oil, cosmetic oils, CBD powder, and protein powder. Masataka warns that this 1 ppm threshold might apply to many CBD raw materials, complicating the production process.
He points out that most cannabinoid raw materials are highly viscous, making it challenging for products like CBD isolate powder to maintain the required particle size. If the aim was to ease restrictions on cannabinoid raw materials, Masataka argues that the current framework falls short. He proposes adding categories like “solid raw materials” to better reflect the industry’s needs.
Italy’s Hemp Sector Faces Uncertain Future
Across Europe, Italy is facing scrutiny from the European Commission (EC) regarding its attempts to ban the trade of CBD and hemp flowers. In July, Italy’s Constitutional Affairs and Justice committees voted on an amendment that would classify all cannabis and hemp flowers as narcotics, regardless of their THC content.
This proposed ban has raised alarms among cannabis trade groups such as Canapa Sativa Italia (CSI) and Federcanapa, who argue that the amendment could violate EU laws on free competition and the movement of goods. The hemp sector in Italy employs over 15,000 people and has a turnover of approximately €500 million ($546 million), making this a significant issue for the economy.
Italian Member of the European Parliament (MEP) Valentina Palmisano confirmed that the EC is currently investigating the amendment. She criticized the proposed changes, stating that they incorrectly equate “cannabis light” with drugs, which contradicts previous rulings by the European Court of Justice.
Germany Expands Access to Medical Marijuana
On a more positive note, Germany has made strides in medical cannabis accessibility. A new law now allows over 70% of physicians to prescribe reimbursed medical marijuana without prior approval from health insurance companies. This change marks a significant development in the country’s approach to cannabis regulation.
Since partial legalization took effect on April 1, adults over 18 can legally possess up to 25 grams of dried cannabis and cultivate up to three plants at home. The new reimbursement proposal for medical marijuana prescriptions under Statutory Health Insurance (GKV) was approved on July 18, covering around 90% of the population.
According to a report by Prohibition Partners, medical marijuana sales in Germany are projected to reach €420 million in 2024 ($260.66 million) and could hit €1 billion by 2028. Historically, 60% of patients paid privately for their prescriptions, but after the legalization changes, that figure has shifted to 80% for private prescriptions.
Despite these advances, only about 2,500 to 3,000 pharmacies are currently dispensing medical marijuana, with some reporting profits as high as €50,000 per month. While this new law may raise insurance costs, it ultimately aims to benefit patients who struggle to afford private prescriptions. A formal evaluation of the law’s impact is set for 2025.
Looking Ahead: The Future of Cannabis in Europe and Beyond
As countries like Japan, Italy, and Germany navigate the complex landscape of cannabis regulation, the industry is at a pivotal moment. With ongoing investigations and evolving guidelines, stakeholders are watching closely to see how these developments will shape the future of cannabis in Europe and beyond. The conversation around cannabis is far from over, and the implications of these changes will continue to unfold in the coming months.
No related posts.
